Home Metabolism Carbohydrate Metabolism inhibitor Voglibose For research use only.

Voglibose

Synonyms: AO 128

Voglibose (AO 128) is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.

Voglibose Chemical Structure

Voglibose Chemical Structure

CAS No. 83480-29-9

Purity & Quality Control

Batch: S410101 DMSO]74 mg/mL]false]Water]74 mg/mL]false]Ethanol]Insoluble]false Purity: 100%
100

Voglibose Related Products

Biological Activity

Description Voglibose (AO 128) is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.
Targets
α-glucosidases [1]
In vitro
In vitro Voglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose. [1]
In Vivo
In vivo Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. [2] Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice. [3] Voglibose (0.001% and 0.005%) stimulates GLP-1 secretion in ob/ob mice, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. Voglibose (0.001% and 0.005%) decreases plasma DPP-4 activity unexpectedly by 40% to 51% in ob/ob mice, resulting from reduced plasma DPP-4 concentrations. Voglibose (0.001% and 0.005%) increases GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively, in ob/ob mice. [4]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01055652 Completed
Type 2 Diabetes Mellitus
AstraZeneca|Bristol-Myers Squibb
 January 2010 Phase 1

Chemical Information & Solubility

Molecular Weight 267.28 Formula

C10H21NO7
CAS No. 83480-29-9 SDF Download Voglibose SDF
Smiles C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 74 mg/mL ( (276.86 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 74 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Voglibose | Voglibose supplier | purchase Voglibose | Voglibose cost | Voglibose manufacturer | order Voglibose | Voglibose distributor